Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in Man, Phase I Study Investigating the Safety and Tolerability of EP395 in Healthy Volunteers

Trial Profile

A First-in Man, Phase I Study Investigating the Safety and Tolerability of EP395 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EP 395 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; First in man
  • Sponsors EpiEndo Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2022 Status changed from recruiting to completed.
    • 13 Apr 2021 According to EpiEndo Pharmaceuticals media release, the first subjects have been dosed in the Company's first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK.The first six healthy subjects have been given a dose of EP395
    • 13 Apr 2021 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top